0000899243-21-004771.txt : 20210203 0000899243-21-004771.hdr.sgml : 20210203 20210203193606 ACCESSION NUMBER: 0000899243-21-004771 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210201 FILED AS OF DATE: 20210203 DATE AS OF CHANGE: 20210203 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fink Eric CENTRAL INDEX KEY: 0001784038 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 21588161 MAIL ADDRESS: STREET 1: C/O GLOBAL BLOOD THERAPEUTICS, INC. STREET 2: 171 OYSTER POINT BLVD., SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-01 0 0001629137 Global Blood Therapeutics, Inc. GBT 0001784038 Fink Eric C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Human Resources Officer Common Stock 2021-02-01 5 A 0 E 322 42.60 A 322 D Common Stock 2021-02-01 4 M 0 3020 A 3342 D Common Stock 2021-02-01 4 F 0 947 49.49 D 2395 D Restricted Stock Units 2021-02-01 4 M 0 3020 0.00 D Common Stock 3020 18120 D Shares acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Represents number of shares of Issuer's Common Stock sold to satisfy the Reporting Person's tax obligations in connection with the vesting of 3,020 shares of Common Stock underlying the Reporting Person's RSUs. The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. /s/ Tricia Suvari, as Attorney-in-Fact 2021-02-03